Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Plymate

Showing results (41-50 of 119) with videos related to

Pageof 12
Sort By:
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|March 4, 2003
17beta-estradiol reduces plasma Abeta40 for HRT-naïve postmenopausal women with Alzheimer disease: a preliminary studyLaura D Baker, Kumar Sambamurti, Suzanne Craft, et al.
Breast Cancer Research and Treatment|June 11, 2013
T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposityDenise L Cecil, Kyong Hwa Park, Ekram Gad, et al.
The Prostate|May 15, 2003
Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1/mac 25) is reduced in human prostate cancer and is inversely related to tumor volume and proliferation index in Lucap 23.12 xenograftsMarie K Tennant, Robert L Vessella, Cynthia C Sprenger, et al.
Neoplasia (New York, N.Y.)|December 3, 2008
Senescence-induced alterations of laminin chain expression modulate tumorigenicity of prostate cancer cellsCynthia C T Sprenger, Rolf H Drivdahl, Lillie B Woodke, et al.
Nature Reviews. Clinical Oncology|August 24, 2018
Alternative splicing in prostate cancerAlec Paschalis, Adam Sharp, Jonathan C Welti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumorsJennifer D Wu, Kathy Haugk, Ilsa Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancerStephen R Plymate, Kathy Haugk, Ilsa Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2011
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variantsElahe A Mostaghel, Brett T Marck, Stephen R Plymate, et al.
Oncotarget|May 16, 2013
Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitorsJoanna L Gillis, Luke A Selth, Margaret M Centenera, et al.
Plos One|November 25, 2011
Androgen receptor variants occur frequently in castration resistant prostate cancer metastasesXiaotun Zhang, Colm Morrissey, Shihua Sun, et al.
Pageof 12

Showing results (41-50 of 119) with videos related to

Sort By:
Pageof 12
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|March 4, 2003
17beta-estradiol reduces plasma Abeta40 for HRT-naïve postmenopausal women with Alzheimer disease: a preliminary studyLaura D Baker, Kumar Sambamurti, Suzanne Craft, et al.
Breast Cancer Research and Treatment|June 11, 2013
T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposityDenise L Cecil, Kyong Hwa Park, Ekram Gad, et al.
The Prostate|May 15, 2003
Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1/mac 25) is reduced in human prostate cancer and is inversely related to tumor volume and proliferation index in Lucap 23.12 xenograftsMarie K Tennant, Robert L Vessella, Cynthia C Sprenger, et al.
Neoplasia (New York, N.Y.)|December 3, 2008
Senescence-induced alterations of laminin chain expression modulate tumorigenicity of prostate cancer cellsCynthia C T Sprenger, Rolf H Drivdahl, Lillie B Woodke, et al.
Nature Reviews. Clinical Oncology|August 24, 2018
Alternative splicing in prostate cancerAlec Paschalis, Adam Sharp, Jonathan C Welti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumorsJennifer D Wu, Kathy Haugk, Ilsa Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancerStephen R Plymate, Kathy Haugk, Ilsa Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2011
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variantsElahe A Mostaghel, Brett T Marck, Stephen R Plymate, et al.
Oncotarget|May 16, 2013
Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitorsJoanna L Gillis, Luke A Selth, Margaret M Centenera, et al.
Plos One|November 25, 2011
Androgen receptor variants occur frequently in castration resistant prostate cancer metastasesXiaotun Zhang, Colm Morrissey, Shihua Sun, et al.
Pageof 12